arrow
C

Claudia Wehr

faculty of medicine
H指数:20
被引数:2,381

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP

ROCK2抑制剤belumosudil对慢性GVHD的疗效与安全性:来自belumosudil MAP大型德奥人群多中心回顾性分析的结果

2026-10-050
PRE
Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation

TP53突变特征及异基因造血细胞移植后急性髓系白血病的结局分析

2026-09-040
OA
Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis

异基因造血细胞移植在晚期系统性肥大细胞增生症中的亚型特异性结局:欧洲肥大细胞增生症专业网络注册研究

2026-08-200
OA
Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

移植前后鲁索利替尼预防可改善接受骨髓纤维化异基因造血细胞移植患者的预后

2026-07-220
OAAI
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

异基因造血干细胞移植后复发的AML患者的突变谱变化

2026-04-030
OAAI
Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors

在去甲基化药物和BCL2抑制剂时代,异基因造血细胞移植后髓系肿瘤复发的供者淋巴细胞输注

2026-03-300
OAAI
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany

德国真实世界、多中心研究中,异基因造血细胞移植后巨细胞病毒预防性使用来特罗维的健康资源利用及成本。

2026-02-160
OAAI
Correction to: An international survey of allogeneic hematopoietic cell transplantation for X-linked agammaglobulinemia
2026-01-210
OAAI
Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation

alloHCT后基于机器学习的一年死亡率预测确定了移植前免疫和炎症的影响

2026-01-190
OA
RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series

RUNX1-FPDMM 在轻度血小板减少症和血小板功能异常家族中的病例系列研究

2025-12-110
OAAI
Usage of rabbit anti-thymocyte / anti-T-lymphocyte globulins (ATG / ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee

兔抗胸腺细胞/抗T淋巴细胞球蛋白(ATG/ATLG)在异基因造血细胞移植中用于血液系统恶性肿瘤的用法:EBMT实践协调与指南委员会的最佳实践建议

2025-11-260
PRE
Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study

异基因干细胞移植进行时间对急性移植物抗宿主病发生率的影响:一项回顾性分析队列研究

2025-08-020
OAAI
The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

系统性炎症反应测量作为异基因造血细胞移植后结局的移植前风险因素的重要性

2025-07-290
OA
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency

年龄依赖性的表型和分子进化:源于GATA2缺乏的儿科MDS

2025-07-150
OAAI
Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST

IDH突变型急性髓系白血病患者在异基因造血干细胞移植后的结局——德国造血干细胞移植与细胞治疗登记处(DRST)代表进行的回顾性分析

2025-05-010
PRE
Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey

Teduglutide治疗难治性严重肠道急性移植物抗宿主病——一项多中心调查

2025-04-140
OA
Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT
2025-01-011
OAAI
Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study
2024-12-011
OAAI